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Background: The identification of the cause of chronic low back pain (CLBP) represents a great challenge to
orthopedists due to the controversy over the diagnosis of discogenic low back pain (DLBP) and the existence of a
number of cases of CLBP of unknown origin. This study aimed to develop diagnostic models to distinguish DLBP
from other forms of CLBP and to identify serum biomarkers for DLBP.
Methods: Serum samples were collected from patients with DLBP, chronic lumbar disc herniation (LDH), or CLBP
of unknown origin, and healthy controls (N), and randomly divided into a training set (n = 30) and a blind test set
(n = 30). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry was performed for protein
profiling of these samples. After the discriminative ability of two most significantly differential peaks from each two
groups was assessed using scatter plots, classification models were developed using differential peptide peaks to
evaluate their diagnostic accuracy. The identity of peptides corresponding to three representative differential peaks
was analyzed.
Results: The fewest statistically significant differential peaks were identified between DLBP and CLBP (3), followed by
CLBP vs. N (5), DLBP vs. N (9), LDH vs. CLBP (20), DLBP vs. LDH (23), and LDH vs. N (43). The discriminative ability of two
most significantly differential peaks was poor in classifying DLBP vs. CLBP but good in classifying DLBP vs. LDH. The
accuracy of models for classification of DLBP vs. CLBP was not very high in the blind test (forecasting ability, 67.24%;
sensitivity, 70%), although a higher accuracy was observed for classification of DLBP vs. LDH and LDH vs. N (forecasting
abilities, ~90%; sensitivities, >90%). A further investigation of three representative differential peaks led to the
identification of two peaks as peptides of complement C3, and one peak as a human fibrinogen peptide.
Conclusions: Our findings benefit not only the diagnosis of CLBP but also the understanding of the differences
between different forms of DLBP. The ability to distinguish between different causes of CLBP and the identification of
serum biomarkers may be of great value to diagnose different causes of DLBP and predict treatment efficacy.
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Low back pain (LBP) is an extremely common musculo-
skeletal disorder that affects an estimated 80% of people
at some time in their lives and represents the most
common cause of disability [1]. Chronic LBP (CLBP)
is the most frequent cause of activity limitation in
adults under the age of 45 [2]. Common causes of LBP
include disc degeneration, lumbar disc herniation (LDH),
lumbar spinal stenosis, lumbar instability syndrome,
and waist soft tissue lesions [3-5]. Clinically, only a small
proportion (~20%) of LBP cases can be attributed with
reasonable certainty to a pathologic or anatomical entity,
because most of the signs and symptoms are not specific
and are difficult to distinguish among diseases that exhibit
LBP [2]. In addition, there exist a significant number of
cases of CLBP of unknown origin. Therefore, an accurate
diagnosis of the cause of LBP represents a great challenge
to orthopedists.
Disc degeneration can cause persistent pain and is
believed to be a major cause of CLBP [6]. Clinical disease
resulting from this pathological process is known as
discogenic low back pain (DLBP). DLBP and LDH are
the two most common causes of CLBP, accounting
for ~40% and ~30% of all cases of CLBP, respectively
[2,7-12]. In contrast to LDH, DLBP is not accompanied by
radicular symptoms or radiological evidence of excessive
activity of nerves or segments [13]. Given that DLBP is
clinically featured with many subjective symptoms,
numerous risk factors, but has few objective positive
markers and unclear pathogenesis, its diagnosis is
often elusive [2]. Discography is currently the main
diagnostic modality for DLBP; however, its reliability
is controversial because discographic results rely heavily
on the reproduction of the patient’s pain and the
operator’s judgment and is therefore largely influenced by
subjective factors. In addition, discography can cause many
complications due to its invasive nature [2]. Thus, there is
an intense debate over discography as a diagnostic tool to
distinguish DLBP from other forms of CLBP and a more
accurate, reliable and non-invasive diagnostic method
is required.
DLBP is caused by a variety of pathologic processes,
including degeneration, endplate damage and inflamma-
tion, which stimulate the intradiscal nociceptors while the
disc periphery remains intact [2]. Normally there is a high
density of blood vessels and nerves in the outer 1/3 of the
annulus fibrosus, but not inside the disc. Degenerated
intervertebral disc induces crack formation in the
endplate and the outer 1/3 of the annulus fibrosus due to
biomechanical reasons. As disc degeneration progresses,
nascent vascular nerve endings grow inward along the
fissure to form inflammatory granulation tissue that
leads to the distribution of vessels and nerves inside
the disc, even within the nucleus pulposus [2]. Duringthis process, biochemical, metabolic, inflammatory and
immuno-reactive products from damaged cells can enter
the bloodstream and alter the blood protein spectrum [9].
Since certain serum proteins can serve as diagnostic
markers for the disease that causes their release from cells
[14], serum proteomic profiling of DLBP will provide a
means to identify diagnostic biomarkers for this clinical
entity. Identification of objective biomarkers in serum that
can aid in differential diagnosis would be of great clinical
benefit.
Most serum proteins, including disease biomarkers,
are often present in small amounts and are difficult to
detect using conventional methods [15]. Capture of
low-abundance proteins is critical for facilitating marker
discovery. Bead-based fractionation can greatly enrich
low-abundance proteins and selectively separate certain
peptides according to different chemical chromatographic
surfaces on the outer layer of magnetic beads. The com-
bination of bead-based fractionation with matrix-assisted
laser desorption ionization time-of-flight mass spectrom-
etry (MALDI-TOF-MS) has been widely used for disease
detection and biomarker identification using human body
fluids (e.g., blood and urine), and carries advantages such
as minimal invasiveness, high efficiency, low cost, and easy
manipulation [16]. The more sophisticated techniques,
such as Fourier transform ion cyclotron resonance tandem
mass spectrometry (MS/MS) and linear trap quadrupole
orbitrap MS, allow the direct identification of peptide
sequences. Currently, there have been no reports of
the use of these techniques for disease detection and
biomarker identification in patients with DLBP.
In the current study, we conducted a MALDI-TOF-MS
analysis of serum samples from patients with DLBP, chronic
LDH, or CLBP of unknown origin, and normal controls,
with an aim to establish diagnostic models for classification
of these different entities and identify serum biomarkers for
differentiation of DLBP from other forms of LBP.
Methods
Patients and serum sample collection
This study included three groups of patients: those with
DLBP (n = 60), CLBP of unknown origin (n = 60), or
chronic LDH (n = 60). All of them were in-patients from
the Department of Orthopedics of the Affiliated Hospital
of Xi’an Jiaotong University or from the Department of
Spine Surgery of the Xi'an Garden City Hospital. Sixty
healthy volunteers were recruited as normal controls
(N). Different groups were matched for race, age and
geographic region. All subjects underwent MRI and CT
examinations and pain evaluation using the visual analogue
scale (VAS) and Oswestry disability index (ODI) (Table 1).
Imaging data for each subject were confirmed by at least
two physicians and a radiologist. Patients who were
suspected of having DLBP based on clinical symptoms and
Table 1 Clinical data for subjects of different groups
Group Case (n) Age (years) VAS value ODI value
Training set DLBP 30 42.81 ± 13.37 6.70 ± 1.86 20.60 ± 8.60
CLBP 30 43.05 ± 15.21 5.48 ± 3.61 25.37 ± 11.24
LDH 30 42.58 ± 9.67 7.21 ± 2.37 31.45 ± 9.07
N 30 41.94 ± 7.65 — —
Blind test set DLBP 30 43.21 ± 12.89 6.90 ± 1.49 21.30 ± 8.78
CLBP 30 41.35 ± 15.43 5.32 ± 3.51 26.21 ± 10.89
LDH 30 43.32 ± 10.21 7.61 ± 2.42 32.21 ± 9.35
N 30 42.84 ± 9.98 — —
Data shown are mean ± standard deviation. DLBP: discogenic low back pain; CLBP: chronic low back pain of unknown origin; LDH: lumbar disc herniation;
N: normal controls; VAS: visual analogue scale; ODI: Oswestry disability index.
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All study subjects gave their informed consent. The study
protocol was approved by the Ethics Committee of the
Xi'an Jiaotong University School of Medicine.
Fasting venous blood samples (5 mL) were drawn from
each subject and placed in vacuum blood collection
tubes containing 2% EDTA-K3. The samples were then
centrifuged at 272 g for 10 minutes at 10°C, and the sera
were collected and stored at −80°C for further use.
Inclusion and exclusion criteria
Inclusion criteria for DLBP were (i) recurrent pain
in the lower back, buttocks, and greater trochanter
for >6 months, which was aggravated after activity,
prolonged sitting or standing; (ii) a negative straight
leg raising test and no lumbar tenderness or nerve
root damage; (iii) normal X-ray, CT results, and normal
MRI results or the presence of “dark disc”, “high imaging
zone” or “modic change” [2]; and (iv) discographic results
revealing abnormal morphology of the disc and induction
of consistent pain, without a pain response in the adjacent
control disc. Exclusion criteria for DLBP were (i) serious
primary diseases of the cardiovascular, digestive, urinary,
hematopoietic or endocrine systems; (ii) mental disorders
and hysteria; (iii) disc injury caused by a one-time severe
trauma; and (iv) a positive iodine allergy test.
Inclusion and exclusion criteria for CLBP of unknown
origin were (i) LBP for >6 months; (ii) negative discographic
results or radiological results ruling out chronic LDH
and degenerative pain caused by the intervertebral
disc; and (iii) no spinal or sacroiliac joint inflammation,
cancer, tuberculosis, deformities, or other organic lesion.
Patients with visceral LBP were also excluded.
Inclusion criteria for chronic LDH were (i) LBP
for >6 months; (ii) recurrent LBP radiating down the leg,
with or without signs of cauda equina compression; (iii)
postural scoliosis, with tenderness in the interspinal lesion
and possible radiating pain caused by pressure on the
sides of spinous processes; (iv) limited spine flexion, a
positive straight leg raising test and augmentation test; (v)sensory dysfunction, decreased muscle strength, and
abnormal reflexes; (vi) X-ray results showing reduction or
disappearance of physiological curvature of the lumbar
spine and narrowed intervertebral space, and CT or MRI
results revealing the compression of nerves or segments
by the disc and excluding spinal tuberculosis, cancer and
other diseases. LDH was diagnosed when (i), (vi) and at
least two of (ii) - (v) were met.
Experimental design
Serum specimens collected from each group were ran-
domly divided into a training set (n = 30) and a blind test
set (n = 30). The training set was analyzed first, followed
by a blind test set to assess model performance and to
qualify biomarkers. The test set was blinded to personnel
processing the samples and analyzing the data.
WCX magnetic bead analysis
Serum samples were placed at 4°C for 2 hours, centrifuged
at 1800 g rpm at 4°C for 10 minutes, aliquoted and stored
at −80°C. Peptides were isolated from the serum using a
magnetic beads-based weak cation exchange (MB-WCX)
kit (Bruker Daltonics, Bremen, Germany) according to
the manufacturer’s instructions. Magnetic beads with
C8-functionality were divided into 5-μL aliquots in a
96-well microtiter plate, which was placed on the mag-
netic beads separation device (MPC-auto96, Dynal, Oslo,
Norway) with the magnet down. Ten microliters of
MB-WCX binding solution and 5 μL of serum sample
were added to the beads and carefully mixed using
the mixing feature of the robot. The sample was
incubated for 30 seconds and the magnet was lifted,
followed by a 30-second waiting interval to settle the
magnetic beads. The supernatant was removed and
the magnet was lowered again. The magnetic beads were
washed three times with MB-WCX washing solution
provided with the kit, lifting and lowering the magnet
as required. The peptides were eluted from the beads
with 10 μL of 50% acetonitrile (ACN) and 2 μL of the
elute was transferred to a fresh 348-well microtiter plate
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(6 μL) was transferred to an auto sample vial containing
54 μL of water and stored for later use. Fifteen microliters
of a-cyano-4-hydroxycinnamic acid (0.3 g/L in ethanol:
acetone 2:1) was added to the 1-μL elute in the 348-well
microtiter plate and mixed carefully. One microliter of this
mixture was spotted in quadruplicate on a MALDI
AnchorChipTM (Bruker Daltonics).
MALDI-TOF MS
MALDI-TOF-MS measurements were performed using
an Ultraflex TOF/TOF instrument (Bruker Daltonics)
equipped with a SCOUT ion source, operating in linear
mode. Ions formed with a N2 pulse laser beam (337 nm)
were accelerated to 25 kV. For MALDI-TOF-MS analysis,
1 μL of the above diluted purified serum peptide was mixed
with 0.5 μL of matrix solution and allowed to dry onto the
MALDI sample plate (600 μM AnchorChip™, Bruker
Daltonics) according to the manufacturer’s instructions.
Two peptides were also included in the matrix solution
for internal calibration: 10 pmol/mL angiotensin II and 10
pmol/mL ACTH18-39 (Bruker Daltonics). Laser desorption
was targeted randomly on the sample plate and samples
were measured using an Autoflex III MALDI-TOF mass
spectrometer (Bruker Daltonics), operating in positive ion
linear (reflection) mode. Ionization was achieved by irradi-
ation with a 50 Hz nitrogen laser. Spectra were the mean of
100 ionizations with fixed laser power in linear geometry
mode and mass maps were obtained in reflectron mode.
The spectra were calibrated externally with a mixture
of protein/peptide standards in the range of 1,000 to
12,000 Da (Bruker Daltonics). The criteria for peak
detection were: signal/noise ratio >5.2 Da peak width
filter, and maximum peak number of 200. For data bank
analysis, all spectra were processed by automatic baseline
subtraction, peak detection, recalibration, and peak area
calculation according to the predefined parameter settings.
The intensities of the peaks of interest were normalized
against the peak intensity of the ACTH internal standard.
These mass shifts were corrected by the FlexAnalysis™
software after alignment with the two internal standards.
Identification of differential peptides
Peptide extracts were dried and re-suspended in 15–20 mL
of 5% formic acid for further MS/MS analysis using a LTQ
mass spectrometer (Thermo Fisher Scientific, Waltham,
USA). Typically, 5 μL of peptide extracts were actually
injected for analysis. For LTQ mass spectrometer analysis,
the peptide extracts were loaded at 15 mL/min for
6 minutes on a nanoAcquity™ column, followed by eluting
and separating on a nanoAcquity™ UPLC™ column, using
90 minute gradients with 95% water, 5% ACN, 0.1%
formic acid (solvent A); and 95% ACN, 5% water, 0.1%
formic acid (solvent B) at a flow rate of 300 nL/min. Thesamples were run in data-dependent mode, where each
full MS scanning was followed by three consecutive MS/MS
scans of the three most abundant peptide molecular ions
(typically doubly and triply charged ions), which were
selected consecutively for collision-induced dissociation.
The MS survey scans (300–2,000 Da) were carried out and
the acquisition cycle consisted of a survey scan at the
highest resolving power (100,000). Dynamic exclusion
was used with a series of parameters and the acquired
MS/MS data were processed using BioworksBrowser
3.3.1. A sequence database search was performed with
the International Protein Index (IPI Human3.45).
Statistical analysis
All MALDI-TOF-MS spectra were analyzed with Flex-
Analysis™ to detect the peak intensities of interest and
CLINPROT™ software to compile the peaks across the
spectra obtained from all samples (Bruker Daltonics).
All statistical comparisons were performed using SPSS
software version 13.0 (SPSS Inc., Chicago, IL, USA).
The non-parametric Wilcoxon test or Kruskal-Wallis test
(>2 classes) was used to compare two peptide peaks, and
the Kruskal-Wallis test was used to compare three or
more peptide peaks. P-values < 0.05 were considered
statistically significant. Neural network algorithm (SNN),
fast classification algorithm (QC) and genetic algorithm
(GA) methods were used to establish specific differences
in the protein diagnostic model and to predict the
diagnostic accuracy. The models based on peptide peaks
showing different peak area were developed, and the best
of the three models was presented.
Results
Detection of differential peptide peaks
In the pair-wise comparisons, processing of MALDI-TOF
spectra resulted in the identification of 3 differential
peptide peaks between DLBP and CLBP of unknown
origin, 23 between DLBP and LDH, 9 between DLBP and
N, 20 between LDH and CLBP of unknown origin, and 43
between CLBP of unknown origin and N and 5 LDH
vs. N. Of note, although there were 95 peaks showing
different peak area between DLBP and CLBP, only three
(1741 m/z, 1898 m/z, and 5754 m/z) of them showed
statistically significant differences. The first two peaks were
up-regulated and the third one was down-regulated in
DLBP. All these peptide peaks, their peak mass, P values,
average peak intensity between two groups and standard
deviation (SD) are shown in Additional file 1 (The character
of different peaks between experimental groups).
Discriminative ability of representative differential
peptide peaks
To examine the ability of differential peptide peaks to
classify different groups of subjects, we selected the two
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and displayed them in scatter plots (Figure 1). A large over-
lapping area between DLBP and CLBP sample distributions
indicated that the two peaks (1741 m/z and 5754 m/z) were
poor at classifying DLBP and CLBP (Figure 1A). In contrast,Figure 1 Scatter plots showing the discriminative ability of represent
(A), DLBP vs. LDH (B), DLBP vs. N (C), CLBP of unknown origin vs. LDH (D), CL
using peaks at 1741 m/z and 5754 m/z, those at 1779 m/z and 1692 m/z, 315
and 2023 m/z and 866 m/z, respectively. The x-axis and y-axis represent the athere was little overlap between DLBP and LDH sample
distributions, indicating that the two peaks (1779 m/z and
1692 m/z) were good at classifying these two groups
(Figure 1B). The ability of other peaks to classify other
groups fell between these two sets of peaks (Figure 1C-F).ative differential peptide peaks. DLBP vs. CLBP of unknown origin
BP of unknown origin vs. N (E), and N vs. LDH (F) were discriminated
9 m/z and 1779 m/z, 1779 m/z and 1692 m/z, 5755 m/z and 7062 m/z,
bundance of each peptide (× for DLBP, ○ for CLBP).
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their diagnostic accuracy
To determine whether multiple peaks could accurately
classify different groups of subjects, models based on
peptide peaks showing different peak area were developed
using GA, SNN and QC. These classification models were
tested for their recognition capability and forecasting
ability, followed by a blind test to calculate their sensitivity
and specificity as diagnostic classification models. Paired
comparison analyses showed that the classification model
for DLBP vs. CLBP had the lowest accuracy, with a recog-
nition capability of 82.66%, a forecasting ability of 67.24%,
and a sensitivity of 70% in the blind test (Table 2). The
classification models for DLBP vs. LDH and LDH vs. N
were more accurate, with forecasting abilities of nearly
90% and sensitivities greater than 90% in the blind test.
We next combined the DLBP and LDH groups as a disc
degeneration group (DLBP + LDH) and compared it with
group N using the above-mentioned algorithms. This
resulted in a recognition capability of 95.82%, a forecasting
ability of 73.28%, and a sensitivity as high as 95% in the
blind test. When combining the DLBP, CLBP, and
LDH groups as a LBP group (DLBP +CLBP + LDH) and
comparing it with group N, we obtained a recognition
capability of 88.86%, a forecasting ability of 73.83%, and a
sensitivity of 86.67% in the blind test. Both combination
groups could be classified from group N accurately (Table 2).
Identification of differential peptides
Protein/peptide markers were chosen based on the
following considerations: (i) significantly differentiallyTable 2 Diagnostic accuracy of different classification models
Comparison Peaks included in the classification model (m
DLBP vs. CLBP 6935.16, 1262.74, 9290.15, 5533.89, 4396.51, 5132
1866.76, 6270.64, 4054.52, 8141.73, 4468.72, 7192
2953.54
DLBP vs. LDH 1692.71,1779.79
DLBP vs. N 1779.28, 3159.06, 5292.71, 5754.98, 4054.22, 5247
4527.3, 7473.04, 3883.04, 6270.34, 3449.05, 5265.2
5131.5
LDH vs. CLBP 1692.72, 1779.74, 7766, 4121.69, 2933.47
LDH vs. N 1866.86, 2023.1, 3263.09, 4527.38, 6938.15, 7639.2
6028.38
CLBP vs. N 5755.18, 4964.69, 1450.69, 5629.16, 4018.94, 2790
9184.37, 7062.96, 5293.26
DLBP + LDH vs. N 7923.02, 2933.11, 2790.11, 6562.89, 5292.65, 1450
5755.42
DLBP + LDH vs. CLBP 1866.85, 1897.7, 8141.79, 5132.49, 5807.7, 5533.54
3192.61
DLBP + CLBP + LDH vs. N 5755.08, 7061.97, 2790.07, 5247.76, 1450.59, 8142
DLBP: discogenic low back pain; CLBP: chronic low back pain of unknown origin; LDexpressed peptides, especially those exhibiting a time- or
dose-dependent pattern; and (ii) peptides that were able to
accurately classify the control group and disease groups.
Taking these into account, three differential peptides
(1692.71 m/z, 1886.86 m/z and 1779.28 m/z) were
selected for peptide identification. By comparing areas of
the selected peptide peaks, we found that the peptides to
which 1779 m/z and 1692.71 m/z corresponded showed
similar expression patterns (Figure 2), with the lowest
expression level in DLBP, followed by CLBP, N and LDH.
Their expression levels differed significantly different
between DLBP and the other three groups (Ps < 0.05 for
all), but not between CLBP of unknown origin, LDH and
N. The peptide peak at 1886 m/z peptide had the largest
area in DLBP, followed by CLBP of unknown origin, LDH
and N. Its expression level also differed significantly
between DLBP and the other three groups (P < 0.05), but
not between CLBP of unknown origin, LDH and N.
MS/MS analysis of the peaks at 1779 and 1692 m/z detected
most b and y ions (Figure 3A and B) and the sequences of
these two peptides were S.SKITHRIHWESASLL.R and
S.KITHRIHWESASLL.R, which corresponded to comple-
ment C3 and complement C3 precursor, respectively.
The peak at 1886 m/z was analyzed by MS/MS and the
sequence of this peptide was identified as R.HRHPDEA
AFFDTASTGK.T, which is unique to fibrinogen alpha chain
precursor (Figure 3C).
Discussion
The diagnosis of the cause of LBP represents a great








82.66% 67.24% 70% 63.33%
88.33% 86.67% 93.33% 80%
.91, 6934.55,
5, 4395.98,
100% 74.71% 86.67% 83.3%
94.89% 81.44% 93.33% 86.67%
8, 5635.59, 95% 86.67% 96.67 93.33%
.29, 4467.25, 95% 76.32% 73.33% 73.33%
.6, 4054.08, 95.82% 73.28% 95% 96.67%
, 4362.7, 90.56% 70.02% 90% 90%
.27 88.86% 73.83% 86.67% 86.67%
H: lumbar disc herniation; N: normal controls.
Figure 2 Comparison of the mean areas of the peaks at 1779 m/z (A), 1692 m/z (B), and 1886 m/z (C) among different groups.
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number of cases of CLBP of unknown origin [2]. There
is currently an urgent need to discover biomarkers for
diagnosis of DLBP and classify it from other forms of
CLBP. In the present study, we used the MALDI-TOF-MS
technology to perform protein profiling of serum
samples from patients with DLBP, chronic LDH, or CLBP
of unknown origin, and healthy controls. By paired
comparison analysis of protein peaks between the
four groups of subjects, we identified a series of peaks
showing significant differential expression between
different groups. We then compared the discriminative
ability of representative differential peptide peaks to
classify different groups of subjects and constructed
diagnostic models using peptide peaks showing different
peak area to evaluate their diagnostic accuracy. We found
that the accuracy of classification of DLBP vs. CLBP was
not very high in the blind test (forecasting ability, 67.24%;
sensitivity, 70%), although a higher accuracy was observed
for classification of DLBP vs. LDH and LDH vs. N
(forecasting abilities, ~90%; sensitivities, >90%). Finally, we
pursued a further investigation of three representative
differential peaks and identified the peaks at 1779 m/z and
1692 m/z as peptides of complement C3, and the peak at
1886 m/z as a human fibrinogen peptide. These results
benefit not only the diagnosis of CLBP but also the
understanding of the differences of different forms of
CLBP. The ability to distinguish between different causes
of LBP and the identification of serum biomarkers may be
of great value in diagnosing different causes of DLBP and
predict treatment efficacy.
The primary purpose of this study was to distinguish
DLBP from CLBP of other causes and identify serum
markers for DLBP. However, the fewest statistically
differential peptide peaks were detected between DLBP
and CLBP of unknown origin, and the diagnostic model
developed based on differential peptides had the lowest
accuracy in the blind test (sensitivity, 70%), although more
statistically differential peptide peaks were detected
and more accurate diagnostic models developed inother pairwise comparison analyses. In patients with
CLBP (including those with DLBP), pain can be caused by
multiple factors, including both discogenic factors and
factors outside the spinal canal [17]. Since current
diagnosis of DLBP relies on discography, its low sensitivity
might have resulted in the misdiagnosis of some cases of
DLBP as CLBP [18]. This may be the main reason for
poor performance of models for classification of DLBP vs.
CLBP in this study.
In our study, two differential peaks (1779 m/z and
1692 m/z) were identified as peptides of complement
C3. Complement C3 is a central molecule in the
complement system and plays a very important role
in inflammatory and immune responses [19]. Interestingly,
the complement system has been implicated in cartilage
degradation, and C3 has been found to be aberrantly
increased in synovial fluids from individuals with
osteoarthritis [20]. However, serum levels of complement
C3 were decreased in our patients with DLBP. The clinical
implications of this finding remain unclear. Given that
complement C3 levels are significantly decreased in
patients with different types of autoimmune diseases
[21,22], and that inflammation secondary to an autoimmune
response to the nucleus pulposus has been implicated
as a primary pain source in DLBP [23], we speculate
that dysregulation of the complement system has a
key role in the pathogenesis of DLBP.
Fibrinogen is a 340 kDa glycoprotein composed of
three polypeptide chains. It is a major player in the
mediation of inflammatory responses and inhibition of
nerve fiber growth and tissue repair processes [24]. Our
finding that serum levels of fibrinogen were signifi-
cantly increased in patients with DLBP indicates a
close relationship between fibrinogen and DLBP. Since
the development of DLBP involves inflammation, nerve
growth and tissue repair, it appears reasonable to surmise
that elevated expression of fibrinogen may be involved in
the pathogenesis of DLBP. Future studies are required to
address the precise role of fibrinogen in the pathogenesis
of DLBP.
Figure 3 MS/MS identification of selected serum peptides as fragments of complement C3 (A) and (B), and isoform 1 of fibrinogen
alpha chain precursor (C). The fragment ion spectra shown were taken for a MS/MS ion search of Protein Knowledgebase (UniProKB)
(http://www.uniprot.org). b and y fragment ion series are indicated together with the limited sequences.
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our study, paired comparison analysis led to the identifica-
tion of 23 significantly differential peaks between DLBP
and LDH. The diagnostic models developed based on these
differential peaks showed a good classification performance
between the two groups. These findings suggest that DLBP
and LDH appear not to share a similar pathogenesis.
Consistent with this, some DLBP patients suffered
pain for more than 300 months but did not develop
LDH until the recent attack.
Conclusions
In conclusion, we have demonstrated that the ClinProt
system is effective in screening differential serum peptides
between different forms of CLBP and searching for
markers to develop diagnostic models for these diseases.
The identification of complement C3 and fibrinogen as
two potential serum biomarkers for DLBP will shed light
on the further understanding of the pathogenesis of
DLBP. In addition, the presence of a significant number of
differential peaks between DLBP and LBP suggests they
appear not to share a similar pathogenesis. However, there
is still a gap between our findings and their application in
clinical practice. Future multi-center, controlled studies
with larger sample sizes are required to determine the
sensitivity and specificity of the two identified serum
biomarkers in the diagnosis of DLBP.
Additional file
Additional file 1: Table S1. The character of different peaks between
experimental groups.
Abbreviations
ACN: Acetonitrile; CLBP: Chronic low back pain; GA: Genetic algorithm;
LBP: Low back pain; LDH: Lumbar disc herniation; MALDI-TOF-MS:
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry;
MB-WCX: Magnetic beads-based weak cation exchange; MS/MS: Tandem
mass spectrometry; N: Normal controls; ODI: Oswestry disability index;
QC: Fast classification algorithm; SD: Standard deviation; S/N: Signal/noise;
SNN: Neural network algorithm; VAS: Visual analogue scale.
Competing interests
All authors declared there were no conflict interests involved.
Authors’ contributions
YGZ made substantial contributions to the conception and design,
acquisition of data, analysis and interpretation of data, and drafting of
the manuscript; TMG carried out the WCX magnetic bead analysis and
MALDI-TOF MS. RQJ participated in the design of the study and
performed the statistical analysis. SXW, and Ma WJM participated in the design
and coordination of the study, and assisted with drafting the manuscript.
All authors carried out the analyses, read, and approved the final manuscript.
Author’s information
Ren-qi Jiang co-first author.
Acknowledgements
This study was supported by grants (Nos. 81371987 and 81171761) from the
National Natural Science Foundation of China and China Scholarship Council.Author details
1Department of Orthopedics, First Affiliated Hospital of Medical College of
Xi’an Jiaotong University, Xi’an 710061, China. 2Department of Sports Injury,
Hong-Hui Hospital, Xi’an Jiaotong University College of Medicine, Xi’an
710054, China. 3Key Laboratory of Environment and Genes Related to
Diseases, Ministry of Education, Xi’an Jiaotong University, Xi’an 710061, China.
Received: 6 May 2014 Accepted: 30 May 2014
Published: 2 June 2014
References
1. Kim SH, Ahn SH, Cho YW, Lee DG: Effect of intradiscal methylene blue
injection for the chronic discogenic low back pain: one year prospective
follow-up study. Ann Rehabil Med 2012, 36(5):657–664.
2. Zhang YG, Guo TM, Guo X, Wu SX: Clinical diagnosis for discogenic low
back pain. Int J Biol Sci 2009, 5(7):647–658.
3. Zhang YG, Guo X, Sun Z, Jia G, Xu P, Wang S: Gene expression profiles of
disc tissues and peripheral blood mononuclear cells from patients with
degenerative discs. J Bone Miner Metab 2010, 28(2):209–219.
4. Zhang YG, Sun Z, Zhang Z, Liu J, Guo X: Risk factors for lumbar
intervertebral disc herniation in Chinese population: a case–control
study. Spine (Phila Pa 1976) 2009, 34(25):E918–E922.
5. Zhang YG, Sun ZM, Liu JT, Wang SJ, Ren FL, Guo X: Features of
intervertebral disc degeneration in rat’s aging process. J Zhejiang Univ Sci
B 2009, 10(7):522–527.
6. Anderson DG, Tannoury C: Molecular pathogenic factors in symptomatic
disc degeneration. Spine J 2005, 5(6 Suppl):260S–266S.
7. Luoma K, Riihimäki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminen A:
Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976)
2000, 25(4):487–492.
8. Barrick WT, Schofferman JA, Reynolds JB, Goldthwaite ND, McKeehen M,
Keaney D, White AH: Anterior lumbar fusion improves discogenic pain at
levels of prior posterolateral fusion. Spine (Phila Pa 1976) 2000, 25(7):853–857.
9. Freemont AJ: The cellular pathobiology of the degenerate intervertebral
disc and discogenic back pain. Rheumatology (Oxford) 2009, 48(1):5–10.
10. Takatalo J, Karppinen J, Niinimäki J, Taimela S, Näyhä S, Järvelin MR,
Kyllönen E, Tervonen O: Prevalence of degenerative imaging findings in
lumbar magnetic resonance imaging among young adults.
Spine (Phila Pa 1976) 2009, 34(16):1716–1721.
11. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N: The
prevalence and clinical features of internal disc disruption in patients
with chronic low back pain. Spine (Phila Pa 1976) 1995, 20(17):1878–1883.
12. Young S, Aprill C, Laslett M: Correlation of clinical examination
characteristics with three sources of chronic low back pain. Spine J 2003,
3(6):460–465.
13. Crock HV: Internal disc disruption: a challenge to disc prolapse fifty years
on. Spine (Phila Pa 1976) 1986, 11(6):650–653.
14. Andersom NL, Anderson NG: The human plasma proteome: history,
character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845–867.
15. Veenstra TD, Conrads TP: Serum protein fingerprinting. Curr Opin Mol Ther
2003, 5(6):584–593.
16. Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a
higher dimension of information content for cancer biomarker
discovery. Nat Rev Cancer 2006, 6(12):961–967.
17. Negrini S, Zaina F: The chimera of low back pain etiology: a clinical
rehabilitation perspective. Am J Phys Med Rehabil 2013, 92(1):93–97.
18. Manchikanti L, Glaser SE, Wolfer L, Derby R, Cohen SP: Systematic review of
lumbar discography as a diagnostic test for chronic low back pain.
Pain Physician 2009, 12(3):541–559.
19. Sahu A, Lambris JD: Structure and biology of complement protein C3, a
connecting link between innate and acquired immunity. Immunol Rev
2001, 180:35–48.
20. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF,
Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A,
Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM,
Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH: Identification of a
central role for complement in osteoarthritis. Nat Med 2011,
17(12):1674–1679.
21. Yan J, Vetvicka V, Xia Y, Hanikýrová M, Mayadas TN, Ross GD: Critical role of
Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized
erythrocytes or soluble beta-glucan. Immunopharmacology 2000, 46(1):39–54.
Zhang et al. BMC Musculoskeletal Disorders 2014, 15:193 Page 10 of 10
http://www.biomedcentral.com/1471-2474/15/19322. Huang S, Tan LM: Research advancement in immunopathogenesis of
myasthenia gravis. Neurosci Bull 2010, 26(1):85–89.
23. Muzin S, Isaac Z, Walker J 3rd: The role of intradiscal steroids in the
treatment of discogenic low back pain. Curr Rev Musculoskelet Med 2008,
1(2):103–107.
24. Kamath S, Lip GY: Fibrinogen: biochemistry, epidemiology and
determinants. QJM 2003, 96(10):711–729.
doi:10.1186/1471-2474-15-193
Cite this article as: Zhang et al.: MALDI-TOF-MS serum protein profiling
for developing diagnostic models and identifying serum markers for
discogenic low back pain. BMC Musculoskeletal Disorders 2014 15:193.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
